BlossomHill BH-30643 and Latigo LTG-001 Achieve Successful NASDAQ IPOs
Recovery in Bio IPO Demand
BlossomHill Therapeutics (BLSM) and Latigo Biotherapeutics (LTGO) were listed on the NASDAQ on August 7, 2026, raising $150 million and $345.6 million, respectively. BlossomHill issued 9.375 million shares at $16 per share, and Latigo issued 19.2 million shares at $18 per share, the upper end of the proposed range, for a combined total of $495.6 million. The fact that both offerings were upsized from their initial plans indicates that institutional investors are selectively returning to the broader biotech sector, focusing on companies with clinical differentiation, late-stage development timelines, and clear competitive advantages.
BH-30643 Targets Tagrisso Resistance
BlossomHill plans to allocate approximately $70 million of the proceeds to its Phase 1/2 SOLARA trial of BH-30643. This candidate is a brain-penetrant, non-covalent macrocyclic EGFR inhibitor in development, targeting classical EGFR mutations, as well as T790M and C797S resistance mutations, and exon 20 insertion mutations. The company plans to hold a meeting with the FDA in the fourth quarter of 2026 to discuss the Phase 1 trial and the possibility of an accelerated approval pathway for C797S-positive advanced non-small cell lung cancer. Currently, AstraZeneca (AZN)'s Tagrisso (osimertinib) is the standard treatment, generating $7.254 billion in sales in 2025. Therefore, the value of BH-30643 lies in demonstrating reproducible responses and brain metastasis control in patients who are resistant to osimertinib, rather than in the overall EGFR market.
LTG-001 Secures Late-Stage Clinical Funding
Latigo plans to use approximately $124.7 million of the proceeds for the Phase 3 trial of LTG-001, a selective NaV1.8 sodium channel inhibitor for acute post-surgical pain, and for commercial preparation. LTG-001 is an oral, non-opioid small molecule in development that directly inhibits NaV1.8 in peripheral nociceptive neurons, unlike opioid analgesics. The competitive benchmark is Journavx (suzetrigine), developed by Vertex Pharmaceuticals (VRTX), which was approved by the FDA on January 30, 2025, for the treatment of moderate-to-severe acute pain in adults, and generated $59.6 million in sales in 2025. Latigo needs to present clinical results that are comparable to Journavx and to acetaminophen, NSAIDs, and opioid combination therapies in terms of efficacy, ease of administration, and insurance coverage.
Expanding into Chronic Pain
Latigo also plans to invest approximately $46.2 million in the Phase 2 trial of LTG-321, a NaV1.8 inhibitor for osteoarthritis, and in preparing for a subsequent Phase 3 trial. This is a portfolio strategy that separates the development of LTG-001 for post-surgical acute pain from LTG-321 for chronic musculoskeletal pain, thereby diversifying the risk. BlossomHill also has an anti-cancer pipeline, including the CLK inhibitor BH-30236, in addition to BH-30643, to reduce its dependence on a single asset. However, a successful IPO does not guarantee clinical success, and the key to future company valuation will be the conversion of the secured capital into patient enrollment rates and regulatory milestones.
The combined $495.6 million upsized offering demonstrates a recovery in risk appetite in the U.S. biotech IPO market, with simultaneous institutional demand for both a Phase 1/2 anti-cancer drug and a Phase 3 pain drug. BlossomHill's BH-30643 targets the EGFR C797S resistance area of Tagrisso, which generated $7.254 billion in sales in 2025, but the key value inflection point will be the FDA meeting in the fourth quarter of 2026 and the subsequent Phase 2 trial design. Latigo's LTG-001 must exceed the efficacy and safety benchmarks set by Journavx and acetaminophen/NSAID/opioid-based standard treatments in the Phase 3 trial, and Journavx's $59.6 million in sales in 2025 provides a benchmark for the initial commercial market. In the medium to long term, the capital raised by both companies will involve dilution, but it will also increase the cash runway to multiple clinical readouts and commercial preparation, making it a benchmark for the valuation of subsequent IPOs and late-stage private biotech companies.
Source: FierceBiotech (rss)